Tivic Health 2025 Q2 Earnings Earnings Loss Narrows but Net Loss Widens

Tivic Health reported its fiscal 2025 Q2 earnings on August 14, 2025. While the company narrowed its per-share loss, the overall net loss widened year over year. The results highlight ongoing financial challenges, with no guidance provided for future earnings or revenue.

Tivic Health’s Q2 results fell short of expectations amid a challenging business environment. The company reported a narrowed per-share loss of $2.19, a 59.2% improvement from the prior year, but its net loss expanded to $1.93 million, representing a 52.5% increase compared to $1.27 million in 2024 Q2. No guidance was provided for future performance, and the company continues to post losses in this quarter for the sixth consecutive year.

Product revenue totaled $94,000, with direct-to-consumer sales accounting for the full amount. A $8,000 return adjusted the revenue to a final total of $86,000, reflecting a 38.6% decline from the $140,000 reported in the same quarter a year earlier. The sharp drop in revenue underscores the challenges in the consumer health segment, which the company plans to exit by year-end.

The company’s net loss widened to $1.93 million in Q2 2025, despite a significant per-share improvement. This reflects the broader financial pressures affecting the business, particularly in the context of its ongoing losses over the past six years.

The stock price of Tivic Health edged down 0.00% during the latest trading day but posted a 11.43% gain for the week. However, it fell 10.49% month-to-date. The stock price dropped sharply on the day after the earnings release, falling 23.2% to $1.52 on August 15, 2025. Holding the stock for a 30-day period following the earnings report did not yield a recovery, and investors who bought on the earnings date faced a significant loss. This pattern suggests that a short-term buy-and-hold strategy around the earnings release is not advisable for TIVC.

Despite the financial challenges, Jennifer Ernst, CEO of Tivic Health, outlined the company’s transformation strategy. The firm is shifting its focus toward biopharma and bioelectronic therapies, with Entolimod as a key late-stage drug candidate for ARS and neutropenia. The company is also advancing next-generation vagus nerve stimulation devices and plans to exit the consumer health tech segment by year-end to concentrate on prescription-based therapeutics. Ernst emphasized the potential for Entolimod in government stockpile opportunities and highlighted regulatory support, including Fast Track and Orphan Drug designations.

Looking ahead, key milestones for 2025 include the transfer of INDs from Statera, GMP manufacturing validation for Entolimod, and the commencement of bioequivalence testing. A planned Type B meeting with the FDA is also expected. While no revenue or EPS guidance was provided, the CFO noted that $7 million in remaining preferred stock tranches will support GMP validation, a critical step for commercialization.

Additional News
Within the three-week period from August 14, 2025, notable non-earnings related news included the Federal Government rolling out a 0% interest loan scheme for tertiary workers, South Korean President Lee Jae Myung pledging respect for North Korea’s political system, and the launch of Nigeria's first humanoid robot games in Beijing. Additionally, a global treaty on plastic pollution collapsed without consensus, and Kogi State saw the successful rescue of six kidnapped victims by Nigerian Army troops.